Effects of sugammadex on coagulation: a systematic review and meta-analysis.

BACKGROUND

Sugammadex, an innovative agent that rapidly and completely reverses rocuronium-induced neuromuscular blockade, may prolong coagulation time and influence postoperative bleeding. This study aimed to investigate the effects of sugammadex on coagulation parameters.

METHODS

Cochrane Central Register of Controlled Trials, Embase, and PubMed were searched on September 25, 2024, for randomized control trials (RCTs) examining the impact of sugammadex on coagulation time.

RESULTS

Five RCTs involving 1328 participants were included. Four RCTs with 1302 participants provided data for the meta-analysis. Sugammadex was found to prolong prothrombin time (PT) without affecting activated partial thromboplastin time (APTT).

CONCLUSIONS

Sugammadex administration may transiently increase PT values without affecting the APTT. Routine coagulation monitoring is not required in healthy individuals; however, individualized assessment should be conducted in high-risk patients. Further studies are warranted to evaluate the coagulation effects of sugammadex in patients with coagulopathies or those receiving anticoagulant therapy.

TRIAL REGISTRATION: This study is registered in the PROSPERO database under the ID CRD42024604567.